biotech / news / / Devdiscourse
Danish pharmaceutical company Zealand Pharma reported a less-than-expected operating loss for the first quarter of the year.
Zealand Pharma reported a smaller-than-expected Q1 operating loss of 539 million Danish crowns.
KEY POINTS
- The company announced a $200 million share buyback, indicating a positive future outlook.
- Zealand expects $700 million from a partnership with Roche tied to petrelintide's Phase 3 trial.
- Advances in Zealand's obesity drug pipeline drove better-than-forecast results for the quarter.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →